Respiratory Medicine
Volume 104, Issue 2 , Pages 228-236 , February 2010

Tiotropium 5μg via Respimat and 18μg via HandiHaler; efficacy and safety in Japanese COPD patients

  • M. Ichinose

      Affiliations

    • Wakayama Medical University, Wakayama, Japan
    • Corresponding Author InformationCorresponding author at: Third Department of Internal Medicine, Wakayama Medical University, 811-1, Kimiidera, Wakayama 641 8509, Japan. Tel.: +81 73 441 0619; fax: +81 73 447 2201.
    • ,
  • T. Fujimoto

      Affiliations

    • Nippon Boehringer Ingelheim, Japan
    • Tsuyoshi Fujimoto, 2-1-1 Osaki, Shinagawa-ku, Tokyo 141 6017, Japan.
    • ,
  • Y. Fukuchi

      Affiliations

    • Juntendo University School of Medicine, Tokyo, Japan
    • Yoshinosuke Fukuchi, 2-9-8-901 Hongo, Bunkyo-ku, Tokyo 113 0033, Japan.

Received 19 August 2009 ,Accepted 17 November 2009.

References 

  1. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest. 2003;123:1441–1449
  2. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317–326
  3. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax. 2006;61:854–862
  4. Tashkin DP, Celli B, Senn S, et al. for UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554
  5. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax. 2000;55:289–294
  6. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47–55
  7. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19:209–216
  8. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217–224
  9. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399–404
  10. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J. 2006;27:547–555
  11. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743–1748
  12. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832–840
  13. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127:809–817
  14. Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;1(Suppl. 12):S19–S24
  15. Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist Inhaler™ and pressurized metered dose inhalers. J Aerosol Med. 2005;18:273–282
  16. Newman SP. Use of gamma scintigraphy to evaluate the performance of new inhalers. J Aerosol Med. 1999;12(Suppl. 1):S25–S31
  17. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ Inhaler compared to deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler. J Aerosol Med. 2005;18:264–272
  18. Caillaud D, Le Merre C, Martinat Y, Aguilaniu B, Pavia D. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2:559–565
  19. van Noord JA, Cornelissen PJG, Aumann J-L, Platz J, Mueller A, Fogarty C. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med. 2009;103:22–29
  20. Pulmonary Physiology Specialist Committee of the Japanese Respiratory Society . Report: standard values for spirometry and partial pressure of blood gas. [in Japanese] J Jpn Respir Soc. 2001;39:1–17
  21. Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Available from http://www.goldcopd.org2007;[accessed 21 August 2008]
  22. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006;130:1695–1703
  23. Kilfeather SA, Ponitz HH, Beck E, et al. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft Mist™ Inhaler in patients with COPD. Respir Med. 2004;98:387–397

PII: S0954-6111(09)00375-8

doi: 10.1016/j.rmed.2009.11.011

Respiratory Medicine
Volume 104, Issue 2 , Pages 228-236 , February 2010

Article Tools

* Image Usage & Resolution